Download Now
Chemotherapeutic drug monitoring could enable precision dosing for increased efficacy, reduced toxicity and increased patient safety in cancer treatments.
Irinotecan, also known as CPT-11 and Campto, is a common antineoplastic chemotherapeutic.
Our highly selective Optimer® binders to irinotecan:
-
Detect both the irnotecan parent drug and primary metabolite SN-38 for complete therapeutic monitoring of the active drug concentration
-
Meet FDA ligand binding assay requirements for the detection and quantification of irinotecan
-
Correlate with LC-MS quantification in clinical patient samples for convenient point-of-care analysis
These Optimer® binders are available immediately for purchase or licensing and can be functionalised for simple platform integration
